Fosun Pharma Q1 2026 Earnings Surge: A Beacon of Chinese Biotech Resurgence
Fosun Pharmaceutical’s 2026 H1 report shows a sharp earnings jump and strong cash flow, hinting at a valuation rebound driven by strategic BD and biotech innovation.
3 minutes to read